As Chief of Medical Dermatology at Stanford Hospital, Dr. Ko brings unparalleled clinical expertise in skin cancer diagnostics and digital health innovation to SkinBit. His pioneering research on AI applications in dermatology, published in Nature, positions him at the forefront of technological advancement in the field.

Beyond his academic contributions, Dr. Ko maintains an active clinical practice specializing in melanoma treatment while also serving as Patient Experience physician lead for Stanford Health Care. This unique combination of clinical excellence, research leadership, and patient-centered care ensures SkinBit's technology meets the highest standards while remaining focused on improving outcomes for patients.

Dr. Sancy Leachman has spent 25 years solving the problem that SkinBit was built to address: catching skin cancer earlier, when it's still curable.

As former Chair of Dermatology at Oregon Health & Science University, she built an advanced imaging center and led Oregon's "War on Melanoma"— a statewide early detection campaign. During this initiative, Oregon's melanoma death rate dropped from 4th-highest in the nation to 31st, representing a 41% decrease — the third-best improvement in the country.

Dr. Leachman also created MoleMapper, one of the first Apple ResearchKit medical apps, which generated the world's largest public collection of skin images for AI research. With twelve years of hands-on experience implementing novel early detection technologies in real clinics, she knows what works for patients and providers — and what doesn't. She brings that hard-won knowledge to SkinBit.

Former Co-Director Melanoma Program at Winship Cancer Center and Director of Pigmented Lesion Clinic at Emory: one of the first in the country to incorporate and study the impact of total body digital photography in the care of patients with atypical nevi.

Outcomes Research in Melanoma & Dysplastic Nevi- Landmark consensus achievements: current national standard of NOT re-excising moderately dysplastic nevi- Consensus initiative: Standard electronic record data elements for diagnostic and longitudinal follow-up.

Dr. Chen brings the methodological firepower to stress-test and strengthen SkinBit's study design, validate Sentinel'sperformance thresholds, and that assure protocols will withstand FDA scrutiny and peer review. Her membership signals the regulatory and academic communities that SkinBit is building this the right way.

• International leader in skin imaging and precision skin cancer prevention.

• More than two decades leading multidisciplinary collaborations spanning dermatology, oncology, engineering, optical sciences, artificial intelligence, and biotechnology.

• Pioneer in total body digital imaging and non-invasive opticaltechnologies, helping establish international standards for skinimaging acquisition, interpretation, and data harmonization.

• Principal investigator and scientific leader of multiple NIH- and industry-supported programs translating novel imaging platforms and biomarkers into clinical practice.

Dr. Curiel is recognized for bringing together diverse scientific disciplines to solve complex clinical problems. Her leadershipin collaborative research, imaging innovation, and technology translation has advanced early skin cancer detection and positioned her as a trusted advisor to both academic and industry partners.

• Authored more than 80 peer-reviewed publications• Holds 17 issued and pending U.S. patents in melanoma biomarkers and imaging systems.

• Co-edited the definitive textbook, Melanoma in Clinical Practice (Springer, 2021).

• Served as Herbert Mescon Endowed Professor and Chair of Dermatology at Boston University for over 15 years (became a top 10 department for research funding under her leadership).

Dr. Alani is one of the most accomplished melanoma physician-scientists in the world, bringing to SkinBit a rare combination of deep scientific rigor, clinical leadership at the highest levels, and a track record of building nationally recognized programs from the ground up. She brings the scientific and clinical authority needed to drive FDA credibility. She is an irreplaceable anchor for the Expert College and a powerful voice when engaging regulators and investors alike.